1
Currently, there is a paucity of data regarding the efficacy of FD-specific treatments. This study aimed to provide an evidence-based analysis of current treatment efficacy for FD. Using PRISMA (Preferred Reporting Items for Systemic Reviews and Meta-Analyses) guidelines. PubMed, Medline, Scopus, and the Cochrane library were searched for articles published in English during 1998-2018. Data regarding treatment regimen and efficacy was graded according to the American College of Physicians grading system (Supplemental Fig 1; available at http://www.jaad.org). 2 , Treatment efficacy of FD was discussed in 20 studies that included 282 patients, of which 73.4% were male. The highest level of evidence was grade 3, encompassing 7 studies with 263 patients (Table I) . [3] [4] [5] [6] [7] [8] A multicenter, retrospective study showed that 15 patients treated with a 10-week course of clindamycin and rifampicin achieved the longest disease remission at an average of 7.2 months. The remission period was shorter among those treated with doxycycline or azithromycin for 3-6 months, who subsequently received adjunct topical antibiotics and intralesional corticosteroids. 3 Powell et al demonstrated that a 10-week course of clindamycin and rifampicin achieved remission in 10 of 18 (55.6%) patients for 2-22 months, and 5 additional patients responded after 2-3 more courses. 4 Similarly, Miguel Gomez et al demonstrated a 91% response rate and longer duration of response (5 months) in cases initially refractory to tetracycline treatment. 5 Conversely, a retrospective study by Tietze et al showed 8 of 12 patients treated with a 10-week course of clindamycin and rifampicin relapsed, and 2 had no clinical response. 6 In another retrospective study, 7 of 10 patients treated with combination tetracycline, clobetasol propionate lotion, and intralesional triamcinolone for an average of 7 months were in disease remission for up to 4 years. Continued treatment with oral antibiotics, intralesional triamcinolone, or clobetasol propionate was needed in 11 of 23 patients to maintain remission. 7 Tietze et al 6 demonstrated that isotretinoin treatment for 5-7 months resulted in disease remission for 4-24 months in 9 of 10 patients, 3 of whom required low-dose maintenance. Of note, treatment of FD with isotretinoin was associated with hyperlipidemia (14/39) in another retrospective review. 8 Newer therapeutic options have been described in case reports and case series in recent years, and accordingly, the level of evidence is very low ( grade 4) (Table II) . 1 Red light photodynamic therapy resulted in clinical improvement in 9 of 10 patients, with 6 patients exhibiting disease remission. 1 Additional treatments with lowest evidence were tacrolimus ointment, external beam radiation, isotretinoin, human immunoglobulin, adalimumab, infliximab, and long-pulse neodymium:yttrium aluminum garnet.
Overall, all studies evaluated had small sample sizes, lacked control groups, and randomization. In addition, given the retrospective nature of the included studies, blinding was not possible so observer bias might have occurred. Combination of clindamycin and rifampicin was the most commonly used treatment in reviewed studies. However, based on low quality of evidence, we are unable to discern whether it is the most efficacious treatment. The lack of higher grade evidence highlights the need for stronger studies performed to assess the efficacy of various treatments used for folliculitis decalvans, though the rarity of FD makes this challenging. Not mentioned 23 total patients; 6 men; follow-up period 3 mon-13 y A. ILT 1 clobetasol propionate lotion 1 (doxycycline 100 mg bid, minocycline 100 mg bid, or tetracycline 500 mg bid) (n = 10) None A. FD in remission in 7/10 (70%) patients, treatment discontinued FD inactive in 3 (30%) patients with continued treatment Topical steroids (n = 48), topical antibiotics (n = 37), tetracycline (n = 36), intralesional steroids (n = 25), rifampicin and clindamycin (n = 21), oral isotretinoin (n = 15), photodynamic therapy (n = 8), oral steroids (n = 5), azithromycin and dapsone (n = 4), topical tacrolimus (n = 3), hydroxychloroquine and minoxidil (n = 2) 
